JAK2 and Venous thrombosis: The current study also confirms the higher rates of arterial and venous thrombosis displayed by JAK2/MPL-mutated patients with ET, compared with type 1/type 1-like CALR-mutated and TN, and that this effect was not accounted for by other independent risk factors for thrombosis including age, gender, thrombosis history or cardiovascular risk factors [20].